For the Inventor, By the Inventor

Enter assignee name

Pola Pharma Inc.

USPTO Granted Patents = 33

% Expired Patents = 21.2

EPO Patents = 18

Forward Citations = 37

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Takaaki Masuda (15 out of 15 patents)

Nobuo Kubota (13 out of 13 patents)

Hirokazu Kobayashi (11 out of 30 patents)

4. Naoko Kobayashi (9 out of 9 patents)

5. Azuma Nishio (8 out of 9 patents)

6. Yasushi Murakami (6 out of 14 patents)

7. Hideaki Sasagawa (5 out of 5 patents)

8. Akira Nozawa (5 out of 10 patents)

9. Madoka Ito (3 out of 7 patents)

10. Hideo Kaneda (3 out of 10 patents)

11. Hiroshi Yamaguchi (3 out of 73 patents)

12. Kahori Fujii (2 out of 2 patents)

13. Eiko Kosugi (2 out of 2 patents)

14. Naoto Nishida (2 out of 6 patents)

15. Yoshiyuki Miyata (2 out of 2 patents)

Core Competencies:

Antifungal Composition

Antimycotic Composition

Pharmaceutical Composition

External-Use Composition

Crystal Habit

Luliconazole

Foamed State

Screen Foamer

Stability Index

Differential Evaluation

2-Nitroimidazole Derivative

33 patents: Sort by Forward Citations

1. 11135297 - External-use composition producing foamed state upon use (2021-10-05),

2. 11090234 - Foam, screen foamer composition, and evaluation method for same (2021-08-17),

3. 10265268 - External composition for screen foamers (2019-04-23),

4. 10130610 - Antimycotic pharmaceutical composition (2018-11-20),

5. 9968591 - Antifungal composition (2018-05-15),

6. 9562912 - Method of identifying abnormal cells by expression levels of ETFB (2017-02-07),

7. 9527836 - Crystal having specific crystal habit and pharmaceutical composition containing the crystal as active ingredient (2016-12-27),

8. 9491933 - Infected nail of animal infected with fungus (2016-11-15),

9. 9480746 - Resin container filled with antifungal pharmaceutical composition (2016-11-01),

10. 9480678 - Antifungal pharmaceutical composition (2016-11-01),

11. 9453006 - Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient (2016-09-27),

12. 9199977 - Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal (2015-12-01),

13. 9145401 - Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation (2015-09-29),

14. 9085554 - Method of evaluating pharmaceutical preparation containing luliconazole and index substance (2015-07-21),

15. 9068958 - Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal (2015-06-30),

Company Overview

Pola Pharma Inc. is a Tokyo-based pharmaceutical company specializing in the development and manufacturing of innovative therapeutic solutions. The organization focuses on various domains, including oncology, cardiovascular health, and central nervous system disorders. With a commitment to advancing healthcare, Pola Pharma engages in extensive research to create effective treatments that address unmet medical needs. Its strategic initiatives are aimed at enhancing patient outcomes through cutting-edge technology and scientific expertise.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

33 Patents

#1,022 in Tokyo

#2,202 in Japan

#20,162 in the World

Pola Pharma Inc.

Forward Citations = 37

27 inventors:

Takaaki Masuda (15 out of 15 patents)

Nobuo Kubota (13 out of 13 patents)

Hirokazu Kobayashi (11 out of 30 patents)

4. Naoko Kobayashi (9 out of 9 patents)

5. Azuma Nishio (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pola Pharma Inc.. Retrieved from https://idiyas.com/company/pola-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…